Contraindications and complications with the use of botulinum toxin

Clinics in Dermatology

Volumn 22, Issue 1, 2004, Pages 66-75

  Klein, Arnold William ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA TOCOPHEROL; AMINOGLYCOSIDE; APRACLONIDINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; CALCIUM CHANNEL BLOCKING AGENT; EMLA; MYDRIATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PHENYLEPHRINE; QUININE;

BLEEDING; BLEPHAROSPASM; CLINICAL TRIAL; DIPLOPIA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRY EYE; DYSTONIA; ECCHYMOSIS; EDEMA; ERYTHEMA; ESTHETIC SURGERY; EYE DISEASE; FACE MUSCLE; FACIAL NERVE DISEASE; HEADACHE; HUMAN; HYPESTHESIA; IMMUNOGENICITY; IMMUNOPATHOLOGY; KERATOPATHY; LIP; MEIGE DISEASE; MIGRAINE; MUSCLE SPASM; MUSCLE WEAKNESS; NECK; PAIN; PRIORITY JOURNAL; PTOSIS; REVIEW; SIDE EFFECT; SPASTICITY; STRABISMUS; TREATMENT CONTRAINDICATION; WRINKLE;

EID: 2442662592     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2003.12.026     Document Type: Article

References (62)

1. Dertzbaugh M.T., West M.W. Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum. Vaccine. 16:1996;1538-1544
2. Lamanns C. The most poisonous poison. Science. 130:1969;763-772
3. Keen M., Blitzer A., Aviv J., et al. Botulinum toxin A therapy for hyperkinetic facial lines results of a double-blind, placebo-controlled study. Plast and Recon Surg. 94:1994;94-99
4. Simpson L.L. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther. 212:1980;16-21
5. Hambleton P. Clostridium botulinum toxins a general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol. 239:1992;16-20
6. Somers E., DasGupta B.R. Clostridium botulinum type A, B, C1 and E produce proteins with or without hemagglutinating activity do they share common amino acid sequences and genes? J Protein Chem. 10:1991;415-425
7. Sakaguchi G. Clostridium botulinum toxins. Pharmacol Ther. 19:1983;165-194
8. Bonventre P.F., Kempe L.L. Physiology of toxin production by Clostridium botulinum types A and B. III. Effect of pH and temperature during incubation on growth, autolysis, and toxin production. Appl Microbiol. 7:1959;374-377
9. Townsend C.T., Yee L., Mercer W.A. Inhibition of the growth of Clostridium botulinum by acidification. Food Res. 19:1954;1-7
10. Baffi R.A., Garnick R.L. Quality control issues in the analysis of lyophilized proteins. Develop Biol Standard. 74:1991;181-184
11. Borodic GE, Ferranter. Orbicularis muscle histology after repetitive injections of botulinum A toxin. Presented in annual meeting of American Academy of Ophthalmology; Atlanta, Georgia; 1990
12. Sloop R.R., Cole B.A., Escutin R.O. Human response to botulinum toxin injection type B compared with type A. Neurology. 49:1999;189-194
13. Mahant N., Clouston P.D., Lorentz I.T. The current use of botulinum toxin. J Clin Neurosci. 7:2000;389-394
14. Lange D.I., Brin M.F., Warner C.L., et al. Distant effects of local injection of botulinum toxin. Muscle Nerve. 10:1987;552-555
15. Olney R.K., Aminoff M.J., Gelb D.J., et al. Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology. 38:1988;1780-1783
16. Bhatia K.P., Münchau A., Thompson P.D., et al. Generalised muscular weakness after botulinum toxin injections for dystonia a report of three cases. J Neurol Neurosurg Psychiatry. 67:1999;90-93
17. Jankovic J., Brin M.F. Botulinum toxin historical perspective and potential new indications. Muscle Nerve. 20:(suppl.):1997;S129-145
18. Brin M.F. Botulinum toxin new and expanded indications. Eur J Neurol. 4:1997;59-66
19. Blitzer A., Binder W.J., Aviv J.E., et al. The management of hyperfunctional facial lines with botulinum toxin a collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg. 123:1997;389-392
20. Binder W., Blitzer A., Brin M.A. Treatment of hyperfunctional lines of the face with botulinum toxin A. Dermatol Surg. 24:1998;1198-1205
21. Tsui J.K.C. Botulinum toxin as a therapeutic agent. Pharmacol Ther. 72:1996;13-24
22. Holds J.B., Alderson K., Fogg S.G., et al. Terminal nerve and motor end plate changes in human orbicularis muscle following botulinum A exotoxin injection. Invest Ophthalmol Vis Sci. 31:1990;178-181
23. Brin M.F., Lew M.F., Adler C.H., et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 53:1999;1431
24. Lingua R.W. Sequelae of botulinum toxin injection. Am J Ophthalmol. 100:1985;305-307
25. Burns C.L., Gammon J.A., Gemmill M.C. Ptosis associated with botulinum toxin treatment of strabismus and blepharospasm. Ophthalmology. 93:1986;1621-1627
26. Scott, AB. Botulinum toxin treatment of strabismus (Focal Points 1989 Clinical Modules for Ophthalmologists, no. 7). San Francisco: American Academy of Ophthalmology, 1989
27. Gonnering R.S. Pharmacology of botulinum toxin. Int Ophthalmol Clin. 33:1993;203-226
28. Wilson, F. Botulinum toxin-A risks overcome by proper technique. Cosmetic Surg Times; Mar, 2001;12
29. Brin M.F., Fahn S., Moskowitz C., et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Movement Dis. 2:1987;237-254
30. Greene P., Kang U., Fahn S., et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 40:1990;1213-1218
31. Blitzer A., Brin M., Fahn S., et al. The use of botulinum toxin in the treatment of focal laryngeal dystonia (Spastic dysphonia). Laryngoscope. 98:1988;193-197
32. Jankovic J., Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 45:1995;1743-1746
33. Gonnering R.S. Negative antibody response to long-term treatment of facial spasm with botulinum toxin. Am J Ophthalmol. 105:1988;313-315
34. Mezaki T., Kaji R., Kohara N., et al. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm a double-blind, controlled study. Neurology. 45:1995;506-508
35. Ludlow CL, Hallett M, Rhew K, et al. Therapeutic use of type F botulinum toxin. N Engl J Med 1992 (letter);326:349-50
36. Sankhla C., Jankovic J., Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord. 13:1998;150-154
37. Göschel H., Wohlfaqrth K., Frevert J., et al. Botulinum A toxin therapy neutralizing and nonneutralizing antibodies - therapeutic consequences. Exp Neurol. 147:1997;96-102
38. National Institutes of Health. Clinical use of botulinum toxin. National Institutes of Health Consensus Development Conference; 1990;8:1-20
39. Borodic G., Johnson E., Goodnough M., et al. Botulinum toxin therapy, immunologic resistance and problems with available materials. Neurology. 46:1996;26-29
40. Botox product monograph. Botox (Botulinum toxin type A) purified neurotoxin complex: Advanced toxin technology. Allergan, Inc., Irvine, CA; 1998; Rx 9161
41. Personal communication from Alastair Carruthers, MD. May, 1999
42. Klein A. Cosmetic therapy with botulinum toxin anecdotal memoirs. Dermatol Surg. 22:1996;757-759
43. Simpson L.L. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 33:1981;155-188
44. Lange D.J., Brin M.F., Fahn S., Lovelace R.E. Distant effects of locally injected botulinum toxin incidence and course. Adv Neurol. 50:1993;609
45. Blitzer A., Brin M.F., et al. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg. 119:1993;1018-1022
46. Carruthers J.D.A., Carruthers J.A. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol surg Oncol. 18:1992;17-21
47. Garcia A., Fulton E. Cosmetic denervation of the muscles of facial expression with botulinum toxin. Dermatol Surg. 22:1996;39-43
48. Hambleton P., Moore A.P. Botulinum neurotoxins origin, structure, molecular actions, and antibody. Moore P. Handbook of botulinum toxin treatment. 1995;16-27 Blackwell Science, Ltd, Oxford
49. Guyuron B., Huddleston S. Aesthetic indications for botulinum toxin. Plast Reconstr Surg; 93:1994;913-918
50. Carruthers, A, Carruthers, J. Cosmetic uses of botulinum A exotoxin. Adv Dermatol 12. Moseby Yearbook, Inc. 1997;325-47
51. Report of the Therapeutics in Technology Assessment Subcommittee of the American Academy of Neurology. Assessment The clinical usefulness of botulinum toxin-A in treating neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 40(9):1990;1332-1336
52. Fraenkel A.S., Kamer F.M. Chemical brow lift. Arch Otolaryngol Head Neck Surg. 124:1998;321-323
53. Carruthers A., Kiene K., Carruthers J. Botulinum A exotoxin use in clinical dermatology. J Am Acad Dermatol. 34:1996;788-797
54. th Annual Clinical and Scientific Meeting of the ASDS; Portland, OR; May, 1998
55. Foster J.A., Barnhorst D., Papay F., et al. The use of botulinum A toxin to ameliorate facial kinetic frown lines. Ophthalmology, 103:1996;618-622
56. Carruthers J., Carruthers A. Botulinum A exotoxin in clinical ophthalmology. Can J Opthalmol. 30:1996;389-400
57. Jankovic J., Brin M.F. Therapeutic uses of botulinum toxin. N Engl J Med. 324:1991;1186-1193
58. Brandt F.S., Bellman B. Cosmetic use of botulinum A exotoxin for the aging neck. Dermatol Surg. 24:1998;1232-1234
59. Carruthers A., Carruthers J.D.A. The use of botulinum toxin to treat glabellar frown lines and other facial wrinkles. Cosmet Dermatol. 7:1994;11-15
60. Bushara K.O., Park D.M. Botulinum toxin and sweating. J Neurol Neurosurg Psychiatry. 57:1994;1437-1438
61. Silberstein S., Mathew N., Saper J., et al. Botulinum toxin type A as a migraine preventive treatment. Headache. 40:2000;445-450
62. Brin, MF, Swope, DM, Abassi, S, et al Botulinum toxin type A (Botox) for migraine: double blind, placebo controlled, region specific evaluation. Poster presented at: Headache World 2000; September, 2000; London, UK. Poster 1196